MP54-02 TWO-YEAR EFFICACY FOLLOW-UP OF A PHASE I TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUÉRIN COMBINED WITH INTRAVENOUS PEMBROLIZUMAB IN RECURRENT OR PERSISTENT HIGH-GRADE NON-MUSCLE-INVASIVE BLADDER CANCER AFTER PREVIOUS BACILLUS CALMETTE-GUÉRIN TREATMENT. (May 2022)